Drug resistance

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Retrieved on: 
Sabato, Giugno 1, 2024
MD, Biomarker, ASCO, DCR, Prognosis, Dicarboxylic acid, Patient, Nivolumab, Annual general meeting, Escape Room, PDAC, Drug resistance, Society, CEACAM1, Yale Cancer Center, Immune system, OS, PFS, Disease, CM24, Death, Tumor microenvironment, Progression-free survival, SOC, Pharmaceutical industry

“These exciting interim data demonstrate the potential of CM24 in combination with nivolumab plus the standard-of-care chemotherapy regimen Nal-IRI/5FU/LV to improve clinical outcomes for advanced metastatic PDAC patients.

Key Points: 
  • “These exciting interim data demonstrate the potential of CM24 in combination with nivolumab plus the standard-of-care chemotherapy regimen Nal-IRI/5FU/LV to improve clinical outcomes for advanced metastatic PDAC patients.
  • These data justify further investigation of CM24 in combination with nivolumab together with standard-of-care chemotherapy to potentially improve outcomes for patients facing a very poor prognosis from this type of tumor”.
  • The primary endpoint of the study is OS and the secondary endpoints include PFS, ORR and DCR.
  • The study interim efficacy results as of the cutoff date of May 8, 2024, are summarized in the following table:

Global Systemic Aspergillosis and Systemic Candidiasis Analysis Report 2024-2030 with Analyst Recommendations - Focus on Personalized Medicine & Penetrating Developing Markets - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Maggio 29, 2024
Health, Pharmaceutical, Patient, USD, Laboratory, Ageing, Research, Azole, Echinocandin, Drug resistance, Polyene, Fungal infection

The "Global Systemic Aspergillosis and Systemic Candidiasis Market (2024 Edition): Analysis By Type (Candidiasis, Aspergillosis), By Treatment Approach, By End User, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Systemic Aspergillosis and Systemic Candidiasis Market (2024 Edition): Analysis By Type (Candidiasis, Aspergillosis), By Treatment Approach, By End User, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Systemic Aspergillosis and Systemic Candidiasis market showcased growth at a CAGR of 3.62% during 2020-2023.
  • The report analyses the Global Systemic Aspergillosis and Systemic Candidiasis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
  • Antifungal drugs continue to serve as the foundation for treating systemic aspergillosis and systemic candidiasis, with azoles, echinocandins, and polyenes representing the primary treatment options.

Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate

Retrieved on: 
Giovedì, Maggio 23, 2024
EC50, Master of Veterinary Science, SARS-CoV-2, Antiviral Research, Science, Virology, COVID19, Conference, Ritonavir, ICAR, Veterinary medicine, Cancer, Drug resistance, Plasma protein binding, Poster, Virus, Pharmaceutical industry

The poster highlights positive results of preclinical experiments using patient isolates of COVID19 virus to define the resistance profile of ratutrelvir, formerly known as travatrelvir or TRX01, Traws’ ritonavir-free Mpro protease inhibitor for COVID19, currently in Phase 1 single and multiple ascending dose (SAD/MAD) escalation studies.

Key Points: 
  • The poster highlights positive results of preclinical experiments using patient isolates of COVID19 virus to define the resistance profile of ratutrelvir, formerly known as travatrelvir or TRX01, Traws’ ritonavir-free Mpro protease inhibitor for COVID19, currently in Phase 1 single and multiple ascending dose (SAD/MAD) escalation studies.
  • “We are very pleased to present the results of resistance studies for ratutrelvir at ICAR2024.
  • We believe the results presented at ICAR provide additional positive data to indicate that ratutrelvir has a differentiated resistance profile compared to nirmatrelvir,” said Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma.
  • The poster can be found on the Scientific Presentations section of the Traws Investor Relations web page.

Purple Biotech Reports First Quarter 2024 Financial Results

Retrieved on: 
Martedì, Maggio 21, 2024
Net, Risk, Tumor microenvironment, SCCHN, FDA, Pancreatic cancer, CA19-9, Oncology, Randomness, NK, Escape Room, Recurrence, AACR, Cancer, STAT3, Table, B cell, Administration, Phase II, PDAC, Average cost, Neoplasm, Safety, Jefferies Group, NSCLC, ADS, Interim, ASCO, Poster, International, Society, Drug resistance, SAB, IGF1R, Nivolumab, Cetuximab, DCR, Patient, Quarter, Pharmacodynamics, Death, Efficacy, CM24, Biomarker, SOC, Annual general meeting, Pharmaceutical industry

REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024.

Key Points: 
  • REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024.
  • Financial Results for the Quarter Ended March 31, 2024
    Research and Development Expenses were $3.4 million for the three months ended March 31, 2024, a decrease of $0.1 million, or 2.8%, compared to $3.5 million in the same period of 2023.
  • As of March 31, 2024, Purple Biotech had cash and cash equivalents and short-term deposits of $10.8 million.
  • A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

Aptose Reports Results for the First Quarter 2024

Retrieved on: 
Martedì, Maggio 14, 2024
RAS, Patient, Prognosis, QT interval, Survival, FLT3, CPK, HMA, VEN, Venetoclax, Food, TUS, Letter, Exercise, FDA, Poster, TP53, SAN, Safety, APS, AML, EHA, Death, Drug resistance, European Hematology Association, SYK, TSX, KIT, Quality of life, Acute myeloid leukemia, Pharmaceutical industry

SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.
  • Clinical sites are now preparing to open the TUS+VEN+HMA triplet study, which is expected to commence enrollment early next quarter.
  • Tuspetinib Preclinical Studies Elucidate Mechanistic Cooperativity Among TUS and VEN – Aptose continues to investigate the mechanisms underlying the complementary activity between TUS and VEN.
  • Aptose intends to submit a compliance plan on or before May 17, 2024, to monitor stockholders’ equity and, if appropriate, consider further available options to evidence compliance with the requirement.

TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board

Retrieved on: 
Mercoledì, Maggio 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Executive, SAB, Publication, Professor, Abstract, Drug resistance, Vanderbilt University, Internal medicine, Roche, Genentech, Doctor of Philosophy, Rush Medical College, Mirati Therapeutics, Mirati, Indiana University, Senior, CBP, Therapy, Assistant, Drug development, Bristol Myers Squibb, Associate, Division, Pharmaceutical industry

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).
  • The company’s lead candidate, TT125-802, is a small molecule CBP/p300 bromodomain inhibitor currently advancing through a Phase 1 clinical trial.
  • “Alan brings extensive experience in drug development, including clinical development experience with one of the leading KRAS inhibitors,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • The team has discovered an exciting pivotal mechanism that governs critical transcriptional resistance pathways,” said Alan Sandler, M.D., Scientific Advisory Board member at TOLREMO.

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Retrieved on: 
Lunedì, Maggio 6, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Technology, Software, Artificial Intelligence, Clinical Trials, Enzyme, Cancer, Prostate, IP, D.C, PDI, Proteinopathy, PMID, Drug resistance, Machine learning, The Journal of Pathology, Breast, MD, Cell, Artificial intelligence, Leukemia, ISSN, Cancer Medicine, Molecular biology, CNS, Giaquinto, Algorithm, Patient, Neoplasm, Lung, Death, Head, Biomarker, Drug development, Therapy, Clinician, Journal, Ovarian cancer, Brain, Oncology Reports, Pharmaceutical industry

(NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.

Key Points: 
  • (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
  • Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.
  • Oregon Therapeutic’s lead drug-candidate XCE853 is known to target PDIs of specific interest for cancer.
  • Oregon Therapeutics is entitled to financial benefits resulting from the out licensing of the background IP to Lantern Pharma.

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Retrieved on: 
Giovedì, Aprile 25, 2024
PFS, Efficacy, Safety, DCR, Risk, Nivolumab, Randomness, SOC, Drug resistance, Death, CM24, Tumor microenvironment, OS, PD-1, PDAC, ASCO, Cancer, Patient, Society, CA19-9, Interim, BMS, Neoplasm, Bristol Myers Squibb, Annual general meeting, Pharmacodynamics, Escape Room, Pharmaceutical industry

REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC), have been selected as late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place on May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • The primary endpoint of the study is overall survival (OS), with progression free survival (PFS) and objective response rate (ORR) as secondary endpoints.
  • The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for hypothesis testing.
  • Approximately 60 patients have been enrolled in the randomized study in 18 centers in the U.S., Spain and Israel.
  • “We are honored to be selected by the ASCO committee with our late breaking abstract poster presentation and are looking forward to presenting our interim results from our randomized Phase 2 CM24 study at the ASCO 2024 annual meeting.” stated Gil Efron, Chief Executive Officer of Purple Biotech.

Microbix Collaborator Introduces New Lab Accreditation Program

Retrieved on: 
Giovedì, Aprile 25, 2024
RUO, Mycoplasma genitalium, EQA, Pelvic inflammatory disease, Infection, OTCQX, Woman, Infertility, Poster, Bacteria, MDX, AMR, ECCMID, TSX, STI, Accreditation, Vertically transmitted infection, Temperature, Drug resistance, Chronic pain, Non-gonococcal urethritis, Ectopic pregnancy, IVD

The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.

Key Points: 
  • The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.
  • The pilot EQA program confirmed the performance of these QAPs across all clinical labs, instrument platforms, and assays.
  • These Mgen QAPs are now available from Microbix as part of its PROCEEDx®FLOQ® (RUO) or REDx™FLOQ® (IVD) catalogue of products.
  • Purchase enquiries for these or other Microbix QAPs can be e-mailed to [email protected] .

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality

Retrieved on: 
Giovedì, Maggio 2, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, GV, Harvard University, Cancer, Genetics, Cell, Broad Institute, Survival, GV (company), Drug resistance, Growth, Overload, Oncogene, Patient, Neoplasm, NIBR, Investment, MIT, Pharmaceutical industry

Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.

Key Points: 
  • Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.
  • “Our activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
  • Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
  • Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways.